Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-13T05:28:22.447Z Has data issue: false hasContentIssue false
  • English
  • Français

Una comparación doble ciego de tianeptina, imipramina y placebo en el tratamiento de episodios depresivos mayores

Published online by Cambridge University Press:  12 May 2020

G. B. Cassano ,
G. Heinze ,
H. Lôo ,
J. Mendlewicz ,
M. Paes de Sousa  and
en nombre del Grupo de Estudio
G. B. Cassano
Affiliation:
Instituto de Psiquiatría, Universidad de Pisa, Pisa, Italia;
G. Heinze
Affiliation:
Instituto Mexicano de Psiquiatría, San Lorenzo Huipulco Delegación Tlapan, Ciudad de México, México;
H. Lôo
Affiliation:
SHU, Hospital de Santa Ana, París, Francia;
J. Mendlewicz
Affiliation:
Laboratorio del Sueño, Departamento de Psiquiatría, Clínica Universitaria de Bruselas, Hospital Erasmo, Bruselas, Bélgica;
M. Paes de Sousa
Affiliation:
Departamento de Psiquiatría, Hospital de Santa María, Lisboa, Portugal
Get access

Resumen

En el curso del desarrollo internacional de la tianeptina (T), 18 centros de Bélgica, Italia, México, Portugal, España y Suiza seleccionaron pacientes deprimidos en un estudio doble ciego de grupos paralelos frente a placebo (P) e imipramina (I). La eficacia y seguridad de la tianeptina se valoraron en 187 pacientes internos deprimidos (56% mujeres, 44% varones) que cumplían los criterios para depresión mayor, con episodio único (24,6%) o recurrente (6 6 ,8 %), o trastorno bipolar depresivo (8 ,6 %). Después de un periodo de rodaje de siete días con placebo previo a la inclusión, los pacientes recibieron tratamiento en condiciones de doble ciego con tianeptina (37,5 mg/d), imipramina (150 mg/d) o placebo durante 14 días, incluido un periodo de tres días de aumento diario de la dosis. Después del decimocuarto día y hasta el final de la sexta semana de tratamiento, se introdujo una dosis flexible de acuerdo con la eficacia terapéutica o los acontecimientos adversos potenciales (T: 25-50 mg/d; I: 100-200 mg/d; P: 2-4 cápsulas).

Keywords

depresióntianeptinaimipraminaplaceboensayo controlado
Type
Artículo original
Information
European Psychiatry (Ed. Española) , Volume 4 , Issue 3 , April 1997 , pp. 171 - 178
Copyright
Copyright © European Psychiatric Association 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

BIBLIOGRAFIA

American Psychiatric Association. Diagnostic and Statistical Manual o f Mental Disorders. DSM-III-R 3rd ed, revised. Washington, APA, 1987.Google Scholar
Angst, JBech, PBoyer, Pet al. Consensus conference on the methodology of clinical triais of antidepressants: report of the Consensus Committee, Zurich, March 1989.Google Scholar
Bobon, DP. Le systeme AMDP. Bruxelles: Mardaga P, 1982.Google Scholar
Chamba, GLemoine, PFlachaire, Eet al. Increased serotonin platelet uptake after tianeptine administration in depressed patients. Biol Psychiatry 1991; 30: 609-17.CrossRefGoogle ScholarPubMed
Chapuy, PCuny, GDelomier, YGalley, PMichel, JPPareaud, MMarey, C. La depression du sujet age. Interet de la tianeptine chez 140 patients traites pendant un an. Presse Med Paris 1991; 20: 1844-52.Google Scholar
Daniel, WW. Applied Nonparametric Statistics. Boston: Houghton Mifflin Company, 1978.Google Scholar
Davis, Jm. Antidepressant drugs. In: Kaplan, HISadock, BJ, eds. Comprehensive Texbook o f Psychiatry/IV. Baltimore, London, Los Angeles, Sidney: Williams and Wilkins, 1985: 1513-37.Google Scholar
Department o f Health and Human Services - Public Health Service Food and Drug Administration Memorandum from P Leber (Director of Division of Neuropharmacological Drug Products) lo Clinical Reviewers and Supervisors - November 5, 1985.Google Scholar
Derogatis, CRLipman, RSRickels, Ket al. The Hopkins Symptom Check-List (HSCL): a self-report symptom inventory. Behav Sci 1974; 19: 1-15.CrossRefGoogle Scholar
Gillings, DKoch, G. The application of the principie of intention-to-treat to the analysis of clinical triais. Drug Inf J 1991; 25: 411-24.CrossRefGoogle Scholar
Guelfi, JD. Efficacy of tianeprine in comparative triais versus reference antidepressants: an overview. Br J Psychiatry 1992; 160: (SUPPL 15): 72-5.CrossRefGoogle Scholar
Guelfi, JDDreyfus, JFLavoisy, J. A controlled study of viloxazine 300 mg sustained release capsules in depressed patients. Drug Invest 1992; 4: 83-8.CrossRefGoogle Scholar
Guelfi, JDDulcire, C, Le Moine, PTafani, A. Clinical safety and efficacy of tianeptine in 1858 depressed patients treated in general practice. Neuropsychobiology 1992; 25: 140-8.CrossRefGoogle ScholarPubMed
Guelfi, JDPichot, PDreyfus, JF. Efficacy of tianeptine in anxious-depressed patients: results of a controlled multicenter trial versus amitriptyline. Neuropsychobiology 1989; 22: 41-8.CrossRefGoogle ScholarPubMed
Guy, W, ECDEU (Early Clinical Drug Evaluation Unit). In: National Institute for Mental Heart, ed. Assessment Manual for Psychopharmacology. Washington, DC: National Institute for Mental Health, 1976.Google Scholar
Hamilton, M. The assessment of anxiety States by rating. Br J Psychology 1959; 32: 50-5.CrossRefGoogle ScholarPubMed
Invemizzi, GAguglia, EBertolino, Aet al. The efficacy and safety of tianeptine in the treatment of depressive disorder: results of a controlled double-blind multicentre study vs amitriptyline. Neuropsychobiology 1994; 30: 85-93.CrossRefGoogle Scholar
Kato, GWeitsch, AF. Neurochemical profile of tianeptine a new antidepressant drug. Clin Neuropharmacol 1988; 11 (suppl 2): S43-S50.Google ScholarPubMed
Kelly, JP, Leonard BE. The effect of tianeptine on the olfactory bulbectomize (OB) rat model of depression. Psychopharmacology 1990; 101 (suppl): S28.Google Scholar
Labrid, CMocaer, EKamoun, A. Neurochemical and pharmacological properties of tianeptine, a novel antidepresant. Br J Psychiatry 1992; 160 (suppl 15): 56-60.CrossRefGoogle Scholar
Labrid, CMoleyre, JPoignant, JCMalen, CMocaer, EKamoun, A. Structure-activity relationship of tricyclic antidepressants, with special reference to tianeptine. Clin Neuropharmacol 1988; 11 (suppl 2): S21-S31.Google ScholarPubMed
Lôo, HDavy, JPZarifian, E. Les antidépresseurs. In: Psychiatrie - Encycl M éd Chir. Paris: Elsevier, 1987; 37860 B70: 1-27.Google Scholar
Lôo, HGanry, HMarey, Cet al. Acceptabilité de la tianeptine chez 170 pat'ients déprimés traites un an. Encéphale 1990; 16; 445-52.Google Scholar
Lôo, HMalka, RDefrance, Ret, al. Tianeptine and amitriptyline: controlled double-blind trial in depressed alcoholic patients. Neuropsychobiology 1988; 19: 79-85.CrossRefGoogle ScholarPubMed
Mendlewicz, J. The social burden of depressive disorders. Neuropsychobiology 1989; 22: 178-80.CrossRefGoogle ScholarPubMed
Mennini, TGarattini, S. Effect of long-term treatment with antidepressants on 3H-serotonin uptake and 3H-imipramine binding in rat brain. J Recept Res 1987; 7: 1-4.Google Scholar
Mocaër, ERettori, MCKamoun, A. Pharmacological antidepressive effects and tianeptine-induced 5-HT uptake increase. Clin Neuropharmacol 1988; 11 (suppl 2): S32-S42.Google ScholarPubMed
Montgomery, SA. Clinically relevant effect sizes in depression. European Neuropsychopharmacology 1994; 4 (special issue).CrossRefGoogle Scholar
Montgomery, SA, Åsberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-9.CrossRefGoogle ScholarPubMed
Olié, JPPoirier, AFLôo, H. Les maladies dépressives. Paris: Flammarion, 1995.Google Scholar
Ostaptzeff, G. Etude contrôlée à double-insu versus imipramine de Tefficacite de la tianeptine dans des états dépressifs non psychotiques. Biol Psychiatry 1981; 5: 597-600.Google Scholar
Pocock, JS. Clinical Triais. A Practical Approach. New York: Wiley and sons, 1983.Google Scholar
Poignant, JC. Etude pharmacologique d’un nouvel antidépresseur: la tianeptine. Biological Psychiatry 1981; 5: 573-8.Google Scholar
Renaud, B, Mocaër, EWeitsch, AFKato, GMennini, TGarattini, S. Stimulation of serotonin uptake induced by a new antidepressant. Pharmacopsychiatry 1988; 21: 66.Google Scholar
The rules goveming medicinal producis in the European Community: guidelines for antidepresant medicinal producis. January 1989.Google Scholar
Thiébot, MHMartin, PPuech, AJ. Animal behavioural studies in the evaluation of antidepressant drugs. Br J Psychiatry 1992; 160 (suppl 15): 44-50.CrossRefGoogle Scholar
Weiss, CGorceix, AKindynis, SDimitriu, M. Etude contrôlée à double-insu versus nomifensine de Tactivité et du délai d’action d’un nouvel antidépresseur la tianeptine. Biol Psychiatry 1981; 5: 593-6.Google Scholar
Whitton, PSSama, GSCurzon, G. Effects of tianeptine on stress-induced behavioural deficits and 5-HT dependent behaviour. Psychopharmacology 1991; 104:81-5.CrossRefGoogle ScholarPubMed
Winer, BJ. Statistical Principies in Experimental Design, 2nd edition. New York: McGraw-Hill, 1971.Google Scholar